Publications

A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.

Copland M. et al, (2023), Br J Haematol

Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape.

Hills RK., (2023), Br J Haematol

Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial.

Freeman SD. et al, (2023), Blood

Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.

Hills RK. et al, (2023), Journal of Clinical Oncology, 41, 508 - 508

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk None. and Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) None., (2023), Lancet, 401, 1277 - 1292

What drives CAR-T emergent cytopenia?

Hills RK., (2023), Br J Haematol

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.

Othus M. et al, (2022), Leuk Lymphoma, 1 - 3

Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.

Love SB. et al, (2022), Trials, 23

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma.

Bewicke-Copley F. et al, (2022), Blood Adv

Unified classification and risk-stratification in Acute Myeloid Leukemia.

Tazi Y. et al, (2022), Nat Commun, 13

A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.

Russell NH. et al, (2022), Br J Haematol, 198, 528 - 534

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.

Russell NH. et al, (2022), Haematologica, 107, 1518 - 1527

Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?

Hills RK., (2022), Br J Haematol, 197, e26 - e27

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2022), Lancet Oncol, 23, 382 - 392

Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials.

Dillon R. et al, (2022), Br J Haematol, 196, e50 - e52

Therapy for isocitrate dehydrogenase 2 (IDH2)R172 -mutant acute myeloid leukaemia.

Linch DC. et al, (2022), Br J Haematol, 196, 1348 - 1352

Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.

Russell N. et al, (2022), Br J Haematol, 196, 1344 - 1347

Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status

Hills RK. et al, (2022), CANCER RESEARCH, 82

Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Lin W-Y. et al, (2022), Nat Commun, 13

High on-treatment platelet reactivity-an OPTIMAl solution, or a better solution?

Hills RK., (2022), Br J Haematol, 196, 272 - 273

Cookies on this website

Publications